+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
I

Actively Recruiting

Researchers are examining the real-world use of bempedoic acid and its fixed dose combination FDC with ezetimibe in adults with primary hypercholesterolemia both heterozygous familial and non-familial or mixed dyslipidemia. This observational study aims to better understand the risks and benefits of these treatments in Asian and Latin American populations where data is currently limited. Participants in this study are adults treated or intended to be treated with bempedoic acid or the combination pill with ezetimibe as part of their regular medical care. No drugs are administered by the study team as it is non-interventional. The study follows patients for one year after starting treatment to collect information on drug reactions and cardiovascular health. During the study, participants health data is collected, including adverse drug reactions, cardiovascular risk, cholesterol levels, inflammatory markers, and uric acid levels. Researchers will review treatment duration and any related adverse events. This follow-up lasts for one year after treatment initiation, monitoring routine clinical outcomes without additional interventions.

Age: 18Years +All Genders
38 locations
C

Actively Recruiting

Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.

Age: 18Years +All GendersPhase 3
206 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
R

Actively Recruiting

Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.

Age: 18Years +All GendersPhase 3
245 locations
S

Actively Recruiting

Researchers are studying the use of zilovertamab vedotin ZV combined with standard treatments for participants aged 18 and older who have relapsed or refractory diffuse large B-cell lymphoma rrDLBCL. This Phase 23, randomized, open-label study aims to evaluate the safety and effectiveness of ZV with treatments like rituximab, gemcitabine, and oxaliplatin R-GemOx, or bendamustine and rituximab BR. The study has two parts Dose Confirmation and Efficacy Expansion, focusing on progression-free survival and other outcomes. Participants will receive intravenous infusions of ZV at doses ranging from 1.5 mgkg to 2.5 mgkg along with R-GemOx or BR depending on their assigned group. Treatments are given on Day 1 of repeated 21-day cycles, continuing for up to six cycles or until disease progression or discontinuation. Some participants will receive standard R-GemOx or BR treatments without ZV. Prophylactic granulocyte colony-stimulating factor G-CSF is also given at each cycle of ZV as per guidelines. During the study, participants undergo assessments including monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations over several months. Researchers will measure overall survival, progression-free survival, objective response rate, and duration of response. Participants will be closely followed for up to approximately 68 months to track safety and effectiveness outcomes throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
135 locations
R

Actively Recruiting

Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.

Age: 18Years +All GendersPhase 3
285 locations
S

Actively Recruiting

Researchers are studying BGB-58067, a drug that blocks a protein called PRMT5, in people with advanced solid tumors that have a deficiency in a gene called MTAP. This study aims to evaluate the safety, side effects, how the drug moves and works in the body, and early signs of anti-cancer activity. The trial includes testing BGB-58067 alone, with standard cancer treatments, and with new anticancer therapies. It is a first-in-human, open-label study with dose escalation and expansion parts. Participants will receive increasing doses of BGB-58067 in various combinations, including monotherapy and with other anticancer agents or standard treatments. The study will find the best dose with manageable side effects and then test that dose in more participants. Although one combination with BG-89894 is discontinued, other combinations continue. Treatment dosing follows specific protocols and schedules determined by the study doctors. Participants will visit clinics regularly for treatment, health monitoring, blood tests, tumor scans, and imaging over about two years. Researchers will watch for side effects, measure drug levels in the blood, and assess tumor response and disease control. The study includes ongoing safety checks and evaluations to understand how the drug affects participants and their cancer over time.

Age: 18Years +All GendersPhase 1
101 locations
S

Actively Recruiting

Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.

Age: 18Years +All GendersPhase 3
217 locations

1-10 of 11

1